Foreign cancer specialists are dissuading claims from a team of Israeli researchers who claim to have developed a concept that would prepare the path to a cancer cure with a US expert that left him as likely "another in a long line of spite, irresponsibility and, finally, false false promises for patients with cancer."
The executive director of the research company told The Times of Israel Tuesday that he has not published his research in medical journals, as is the norm, because "it can not be allowed" to do so, but that the results of his pre-Clinical trials have been "very good". Several Israeli experts contacted by The Times of Israel refused to comment on the lawsuit, some precisely because they were not familiar with the investigation.
"We are working on a complete cancer care," said Ilan Morad, the general director and founder of the Nes Ziona Initiative, Accelerated Evolution Biotechnologies Ltd. (AEBi), in an interview with The Times of Israel on Tuesday, echoing the company claims made at Jerusalem Post earlier this week. "We still have a long way to go, but in the end we believe that we will take care of all kinds of patients with cancer and with few side effects."
Morad added that "in a year or so," the company could begin to treat patients as part of the clinical trials that he expects to start if the funds increase. The family of molecules it has developed, which are the nucleus of its ostensible path to care, have been tested in preclinical Israeli tests on human cancer cells in a laboratory and in mice, Morad said, and it was found to be effective In the common orientation lung cancers, colon cancer and head and neck cancer.
Several hospitals and experts in Israel refused to comment on the claims, some observing that they did not have direct information about the investigation. Other experts, abroad, sounded remarkable warnings about the claims of the researchers.
Dr. Leonard Lichtenfeld, deputy chief of the medical officer of the National Office of the American Cancer Society, said on Tuesday that while Israeli scientists had worked "with an interesting approach to interfere with the ability to work cancer cells, "his research has been" apparently not published in the scientific literature, where he could be subjected to review, support and / or criticism from colleagues. "
"We all have the hope that a cure for cancer can be found quickly. Without a doubt, this approach may work," he wrote in a blog post titled "A Cure for Cancer? Not too fast."
"However, as the experience has taught us so many times, the gap of a successful mouse experiment for the effective and beneficial application of exciting laboratory concepts to help patients Cancer in bed is, in fact, a long and tragic trip, full of unplanned and unforeseen obstacles. "
"It is likely that it will take some time to show the benefit of this new approach to the treatment of cancer. And unfortunately, from other similar reclamations of advanced technologies for the treatment of cancer, the odds are that will not be successful ".
Lichtenfeld added: "We hope that this approach is also fruitful and successful. At the same time, we should always offer a precautionary note that the process to get this mouse treatment in the home is not always a simple and simple trip ".
Ben Neel, director of the Perlmutter Cancer Center of NYU Langone Health, told The New York Post that "cancer is a multiple illness, and it is very unlikely that this company has found cancer" cure "more than just one cure for infections ".
He said that "most likely, this claim is another in a long line of false, irresponsible and, ultimately, fake cruel promises for cancer patients."
Post the … investigate?
Morad said the AEBi team chooses to use the scarce funds to do more research and not publish their research in medical journals.
The company wants to focus on "advancing research and developing more targeting peptides. It takes a lot of work and we are a small company," said The Times of Israel. "We can not afford to. Publishing an article brings many efforts and lots of funds, and we can not afford it.
He added: "If it were a large company with many funds, this would be the first thing we would do. If I have $ 100,000, what can I spend?" He asked. "Advance the search and find more targeting peptides, or do many experiments to write an article? What would you do, if you have to choose?"
In the conventional development process, medical researchers who make a discovery collect their material and send a document about it legitimately for medical journals with the hope that the editorial committees of journals validate their findings and publish the discovery . The higher the prestige of the publication, the greater the apparent value of the discovery. Researchers do not have to pay legitimate medical journals to publish their findings.
A "pop" armed with peptides
The drug that the company hopes to develop "will be a personalized medication that will be adapted to the specific cancers of each patient," Morad said. "Each person will get the medication for their specific cancer."
The treatment, which the company calls MuTaTo (multi-objective toxin), is a family of molecules armed with peptides that have the ability to interact with a large variety of proteins expressed by cancer cells . Instead of going to a type of protein, molecules have the ability to attack several proteins at the same time, Morad said. "We created a multiple cancer attack," he said.
"Think in the arms of a pop," he elaborated. "The octopus in this case is the molecule and, at the end of each arm, there are peptides that interact with proteins and inhibit their action." This interaction allows the toxic peptides that adhere to many arms of the pulp penetrate into the cancerous cell and destroy it from the inside.
The results of preclinical trials, Morad said, were "very good", showing that molecules have the ability to kill cancer cells, only directed to them and not to other healthy cells. "The effect is specific to cancer cells, leaving out other non-cancerous cells, so that the side effects will be much less. It will have side effects at the ibuprofen level or a side effect common aspirin ".
The company is now in the process of patenting the concept, he said. Funds to date come from private investors.
Morad founded AEBi in the year 2000, having previously worked as a researcher at Peptor Ltd., a biopharmaceutical company based in Rehovot, which in 2003 obtained the green light for a merger with the German biopharmaceutical company DeveloGen. Other team members include Dan Aridor, the chairman of the board, who specialized in finance at Columbia Business School, according to the company's website.
The third member mentioned on the website is Hanan Itzhaki, the chief operating officer of the company. Itzhaki has been in the firm since 2002, having worked previously in InSight Pharmaceutical Ltd., based in Rehovot, he held a postdoctoral position in the horticultural department of Purdue University in Indiana and has a doctorate in the Faculty of Agriculture of the Hebrew University of Jerusalem.
Morad said that the team now intends to advance its research and reach clinical trials as quickly as possible.
The United States Food and Drug Administration establishes procedures for the development and process of drugs in the following manner: "Before a drug can be tested on people, the company or sponsor conducts laboratory tests and Animals to discover how the drug works and if it is likely to be safe and work well in human beings. Next, a series of tests are started to determine if the medication is safe when used to treat an illness and if it provides a real benefit to health. "